Tag Archives: GSK

GSK’s Omjjara Receives EU Approval for Myelofibrosis Treatment

(IN BRIEF) GSK has received marketing authorization from the European Commission for Omjjara (momelotinib), an oral inhibitor targeting JAK1/JAK2 and activin A receptor type 1 (ACVR1). Omjjara is the first approved treatment in the EU for disease-related splenomegaly (enlarged spleen) … Read the full press release

GSK Seeks Regulatory Approval to Extend RSV Vaccination to At-Risk Adults Aged 50-59

(IN BRIEF) GSK has submitted a regulatory application to the European Medicines Agency (EMA) to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. The … Read the full press release

GSK’s Dostarlimab Shows Positive Results in Endometrial Cancer Trial

(IN BRIEF) GSK plc has announced positive results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial, evaluating the use of Jemperli (dostarlimab) in combination with standard chemotherapy and as maintenance therapy for patients with primary advanced or recurrent endometrial … Read the full press release

GSK’s Jemperli Gains EC Approval for Advanced Endometrial Cancer Therapy

(IN BRIEF) In a significant development, GSK plc has received marketing authorization from the European Commission (EC) for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy as a treatment option for adult patients suffering from mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) … Read the full press release

GSK’s Belantamab Mafodotin Shows Promise as Second-Line Treatment for Multiple Myeloma in Phase III Trial

(IN BRIEF) GlaxoSmithKline (GSK) has reported positive results from the interim efficacy analysis of the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial successfully met its primary endpoint of … Read the full press release

GSK Initiates Phase III Trials for Low Carbon Inhaler to Drastically Cut Emissions

(IN BRIEF) GSK, a leading pharmaceutical company, has unveiled plans to conduct Phase III trials in 2024 for a low carbon version of its popular inhaler, Ventolin (salbutamol). The initiative aims to reduce greenhouse gas emissions associated with the inhaler’s … Read the full press release

ViiV Healthcare Receives Chinese Approval for Long-Acting HIV Treatment Vocabria and Rekambys

(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release

GSK’s ViiV Healthcare to Share Latest Advances in HIV Treatment and Prevention at EACS 2023

(IN BRIEF) ViiV Healthcare, a global specialist HIV company, will present 23 abstracts at the 19th Annual European AIDS Conference (EACS 2023). These abstracts will cover various aspects of HIV treatment and prevention, including real-world data on long-acting and 2-drug … Read the full press release

GSK’s Jemperli Receives Positive CHMP Opinion for Frontline Treatment of Advanced Endometrial Cancer with Chemotherapy

(IN BRIEF) GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of Jemperli (dostarlimab) in combination with chemotherapy as a frontline treatment for adult … Read the full press release

Seasoned Marketer Suresh Balaji Joins Lloyds Banking Group as CMO

(IN BRIEF) Lloyds Banking Group has appointed Suresh Balaji as its Chief Marketing Officer, effective from October 16. In his new role, Balaji will oversee the Brand, Marketing, and Experience function for the group. He will be responsible for developing … Read the full press release

GSK Resolves California Zantac Litigation Through Confidential Settlements

(IN BRIEF) GlaxoSmithKline (GSK) has announced a confidential settlement in the Cantlay/Harper case filed in California state court, which was scheduled for trial in November 2023. Additionally, GSK has settled the three remaining breast cancer bellwether cases in California, effectively … Read the full press release

GSK Forms Exclusive Partnership with Zhifei to Promote Shingrix Vaccine in China

(IN BRIEF) GSK plc has announced an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to co-promote GSK’s shingles vaccine, Shingrix, in China for an initial three-year period, with the potential for extension. Zhifei, China’s largest vaccine company by … Read the full press release

GSK’s Arexvy RSV Vaccine Approved in Japan for Adults Aged 60 and Above, a First for the Country

(IN BRIEF) GSK plc has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) to prevent respiratory syncytial virus (RSV) disease in adults aged 60 and above. This marks … Read the full press release

GSK and Save the Children Extend Partnership to Boost Child Vaccination Rates in Ethiopia and Nigeria

(IN BRIEF) Pharmaceutical company GSK and international non-profit organization Save the Children have renewed their partnership for another five years, with GSK committing £15 million to the initiative. The collaboration will primarily focus on increasing child vaccination rates and reducing … Read the full press release

Nestwork Launches Peer-to-Peer Career Discovery Platform with £175,000 Investment

(IN BRIEF) A team led by current students and recent graduates has created Nestwork, a new platform that leverages peer-to-peer learning to help students find and secure their ideal careers. The platform simplifies career discovery through technology while supporting university … Read the full press release

Sandoz acquires Mycamine, reinforcing its anti-infectives portfolio

(IN BRIEF) Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas. This acquisition will reinforce Sandoz’s hospital … Read the full press release

Sandoz adquiere Mycamine, reforzando su cartera de antiinfecciosos

(NOTICIA EN BREVE) Sandoz, líder mundial en medicamentos sin patente (genéricos y biosimilares), ha firmado un acuerdo para adquirir los derechos de producto a nivel mundial del agente antifúngico sistémico líder Mycamine® (micafungina sódica, Funguard® en Japón) de Astellas. Esta … Read the full press release

New practical guide for businesses to measure air pollutant emissions across value chains

The Alliance for Clean Air, launched by the World Economic Forum and the Clean Air Fund, published a practical guide on how businesses can quantify the air pollutant emissions along their value chains The Alliance for Clean Air has adopted … Read the full press release

Nueva guía práctica para que las empresas midan las emisiones de contaminantes atmosféricos en las cadenas de valor

La Alianza para el Aire Limpio, lanzada por el Foro Económico Mundial y el Fondo de Aire Limpio, publicó una guía práctica sobre cómo las empresas pueden cuantificar las emisiones de contaminantes del aire a lo largo de sus cadenas … Read the full press release

Tony Wood tritt die Nachfolge von Dr. Hal Barron als Chief Scientific Officer bei GlaxoSmithKline R&D an

Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022 vom CSO zu einem GSK Non-Executive Director mit zusätzlichen Verantwortlichkeiten zur Unterstützung von Forschung und Entwicklung (PRESSEMITTEILUNG) LONDON, 19-Jan-2022 — … Read the full press release